{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T21:51:06Z","timestamp":1784065866441,"version":"3.55.0"},"reference-count":40,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2023,8,10]],"date-time":"2023-08-10T00:00:00Z","timestamp":1691625600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Second Department of Neurology at the Institute of Psychiatry and Neurology"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Life"],"abstract":"<jats:p>Wilson\u2019s disease (WD) is a genetic disorder with copper accumulation in various tissues leading to related clinical symptoms (mainly hepatic and neuropsychiatric) which can be in 85% of patients successfully treated with anti-copper agents. However, during WD treatment neurological deterioration may occur in several patients. D-penicillamine (DPA) is one of the most frequently used drugs in WD treatment. Despite its efficacy, DPA can produce many adverse drug reactions, which should be recognized early. We present the case of a 51-year-old man diagnosed with the hepatic form of WD and initially treated with DPA in whom after 15 months of treatment, diplopia and evening ptosis occurred. WD treatment non-compliance as well as overtreatment were excluded. Supported by neurological symptoms, a positive edrophonium test, and high serum levels of antibodies against acetylcholine receptors (AChR-Abs), as well as low concentrations of antibodies against muscle-specific kinase (MuSK-Abs), the diagnosis of myasthenia gravis (MG), induced by DPA, was established. DPA was stopped; zinc sulfate for WD and pyridostigmine for MG symptoms were introduced. Diplopia and ptosis subsided after a few days, which supported our diagnosis. During a follow-up visit after 6 months, the patient did not present any MG symptoms. AChR-Abs level gradually decreased and MuSK-Abs were no longer detected. Pyridostigmine was stopped, and within 9 months of follow-up, the neurological symptoms of MG did not reoccur. The authors discussed the patient\u2019s neurological deterioration, performed a systematic review of DPA-induced MG in WD and concluded that MG is a rare and usually reversible complication of DPA treatment. DPA-induced MG generally occurs 2\u201312 months after treatment initiation and ocular symptoms predominate. Response to pyridostigmine treatment is good and MG symptoms usually reverse within one year after DPA treatment cessation. However, symptoms may persist in some cases where DPA treatment is only a trigger factor for MG occurrence.<\/jats:p>","DOI":"10.3390\/life13081715","type":"journal-article","created":{"date-parts":[[2023,8,10]],"date-time":"2023-08-10T10:11:22Z","timestamp":1691662282000},"page":"1715","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["D-Penicillamine-Induced Myasthenia Gravis\u2014A Probable Complication of Wilson\u2019s Disease Treatment\u2014A Case Report and Systematic Review of the Literature"],"prefix":"10.3390","volume":"13","author":[{"given":"Agnieszka","family":"Antos","sequence":"first","affiliation":[{"name":"Second Department of Neurology, Institute of Psychiatry and Neurology, 02-957 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1956-1866","authenticated-orcid":false,"given":"Anna","family":"Cz\u0142onkowska","sequence":"additional","affiliation":[{"name":"Second Department of Neurology, Institute of Psychiatry and Neurology, 02-957 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Bembenek","sequence":"additional","affiliation":[{"name":"Department of Clinical Neurophysiology, Institute of Psychiatry and Neurology, 02-957 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iwona","family":"Kurkowska-Jastrz\u0119bska","sequence":"additional","affiliation":[{"name":"Second Department of Neurology, Institute of Psychiatry and Neurology, 02-957 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2670-9651","authenticated-orcid":false,"given":"Tomasz","family":"Litwin","sequence":"additional","affiliation":[{"name":"Second Department of Neurology, Institute of Psychiatry and Neurology, 02-957 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,8,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"European Association for The Study of The Liver (2012). EASL Clinical Practice Guidelines: Wilson\u2019s disease. J. Hepatol., 56, 671\u2013685.","DOI":"10.1016\/j.jhep.2011.11.007"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41572-018-0018-3","article-title":"Wilson disease","volume":"4","author":"Litwin","year":"2018","journal-title":"Nat. Rev. Dis. Primers."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/B978-0-444-63625-6.00015-X","article-title":"Wilson disease\u2014Currently used anticopper therapy","volume":"142","author":"Czlonkowska","year":"2017","journal-title":"Handb. Clin. Neurol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/S2468-1253(17)30293-5","article-title":"Bis-choline tetrathiomolybdate in patients with Wilson\u2019s disease: An open label, multicentre, phase 2 study","volume":"2","author":"Weiss","year":"2017","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"S68","DOI":"10.21037\/atm.2018.12.09","article-title":"Wilson disease\u2014Treatment perspectives","volume":"7","author":"Litwin","year":"2019","journal-title":"Ann. Transl. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.cgh.2013.11.009","article-title":"Long-term outcome for Wilson disease: 85% good","volume":"12","author":"Schilsky","year":"2014","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Antos, A., Cz\u0142onkowska, A., Smolinski, L., Bembenek, J., Przyby\u0142kowski, A., Skowronska, M., Kurkowska-Jastrz\u0119bska, I., and Litwin, T. (2023). Early neurological deterioraion in Wilson\u2019s disease: A systematic literature review and meta-analysis. Neurol. Sci.","DOI":"10.1007\/s10072-023-06895-6"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Litwin, T., Antos, A., Bembenek, J., Przyby\u0142kowski, A., Kurkowska-Jastrz\u0119bska, I., Skowro\u0144ska, M., and Cz\u0142onkowska, A. (2023). Copper deficeicny as Wilson\u2019s disease overtreatment: A systematic review. Diagnostics, 13.","DOI":"10.3390\/diagnostics13142424"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"595","DOI":"10.5603\/PJNNS.a2021.0080","article-title":"D-penicillamine-induced lupus erythematosus as an adverse reaction of treatment of Wilson\u2019s disease","volume":"55","author":"Antos","year":"2021","journal-title":"Neurol. Neurochir. Pol."},{"key":"ref_10","unstructured":"Litwin, T., Czlonkowska, A., and Socha, P. (2019). Clinical and Translational Perspectives on Wilson Disease, Academic Press."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.cgh.2013.09.025","article-title":"Long-term outcomes of patients with Wilson disease in a large Austrian cohort","volume":"12","author":"Beinhardt","year":"2014","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1478-3231.2010.02354.x","article-title":"Long-term follow-up of Wilson disease: Natural history, treatment, mutations analysis and phenotypic correlation","volume":"31","author":"Bruha","year":"2011","journal-title":"Liver Int."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/ene.13171","article-title":"Exchangeable copper: A reflection of the neurological severity in Wilson\u2019s disease","volume":"24","author":"Poujois","year":"2017","journal-title":"Eur. J. Neurol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1111\/ene.12348","article-title":"D-penicillamine versus zinc sulfate s first-line therapy for Wilson\u2019s Disease","volume":"21","author":"Litwin","year":"2014","journal-title":"Eur. J. Neurol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1016\/S0140-6736(00)05186-2","article-title":"Myasthenia gravis","volume":"357","author":"Vincent","year":"2001","journal-title":"Lancet"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/nrneurol.2016.44","article-title":"Myasthenia gravis\u2013autoantibody characteristics and their implications for therapy","volume":"12","author":"Gilhus","year":"2016","journal-title":"Nat. Rev. Neurol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1093\/ejcts\/ezu309","article-title":"Prognostic factors of remission in myasthenia gravis after thymectomy","volume":"48","author":"Mao","year":"2015","journal-title":"Eur. J. Cardiothorac. Surg."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"W65","DOI":"10.7326\/0003-4819-151-4-200908180-00136","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions. Explanation and elaboration","volume":"151","author":"Liberati","year":"2009","journal-title":"Ann. Intern. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"644","DOI":"10.31729\/jnma.7607","article-title":"D-penicillamine induced myasthenia gravis in Wilson\u2019s disease: A case report","volume":"60","author":"Thapa","year":"2022","journal-title":"JNMA J. Nepal. Med. Assoc."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"S74","DOI":"10.21037\/atm.2019.04.31","article-title":"The interesting case-orphan diseases-double trouble","volume":"7","author":"Reuner","year":"2019","journal-title":"Ann. Transl. Med."},{"key":"ref_22","first-page":"323","article-title":"Concurrent massive breast enlargement, myasthenia gravis and dermopathy as manifestations of penicillamine toxicity in a Wilson\u2019s disease patient","volume":"67","author":"Tan","year":"2012","journal-title":"Med. J. Malaysia"},{"key":"ref_23","first-page":"293","article-title":"D-Penicillamine induced myasthenia gravis","volume":"7","author":"Varghese","year":"2002","journal-title":"Neurosciences"},{"key":"ref_24","first-page":"648","article-title":"Generalized myasthenia gravis following use of D-pencillamine in Wilson\u2019s disease","volume":"47","author":"Narayanan","year":"1999","journal-title":"J. Assoc. Physician India"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/0002-9343(77)90153-X","article-title":"Penicillamine-associated myasthenia gravis, antiacetylcholine receptor and antistriational antibodies","volume":"63","author":"Masters","year":"1977","journal-title":"Am. J. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1136\/bmj.2.5973.726-a","article-title":"Myasthenia syndrome during penicillamine treatment","volume":"28","author":"Czlonkowska","year":"1975","journal-title":"Br. Med. J."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jneuroim.2012.05.011","article-title":"Anti-MuSK and anti-AChR-positive myasthenia gravis induced by d-penicillamine","volume":"250","author":"Poulas","year":"2012","journal-title":"J. Neuroimmunol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1097\/00000441-199504000-00001","article-title":"D-penicillamine-induced myasthenia gravis: Diagnosis obscured by coexisting chronic obstructive pulmonary disease","volume":"309","author":"Adelman","year":"1995","journal-title":"Am. J. Med. Sci."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1590\/S0004-282X1984000400010","article-title":"Myasthenia gravis induced by D-penicillamine in a patient with progressive systemic sclerosis","volume":"42","author":"Marchiori","year":"1984","journal-title":"Arq. Neuropsiquiatr."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1136\/ard.41.6.617","article-title":"Multiple side effects of penicillamine therapy in one patient with rheumatoid arthritis","volume":"41","author":"Essigman","year":"1982","journal-title":"Ann. Rheum. Dis."},{"key":"ref_31","first-page":"1171","article-title":"D-penicillamine and the ocular myasthenic syndrome","volume":"13","author":"Kimbrough","year":"1981","journal-title":"Ann. Ophthalmol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/S0165-5728(99)00038-7","article-title":"T cell responses to D-penicillamine in drug-induced myasthenia gravis: Recognition of modified DR1:peptide complexes","volume":"97","author":"Hill","year":"1999","journal-title":"J. Neuroimmunol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"660","DOI":"10.3389\/fneur.2020.00660","article-title":"Mu-SK-associated myasthenia gravis: Clinical features and management","volume":"11","author":"Rodolico","year":"2020","journal-title":"Front. Neurol."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Sheikh, S., Alvi, U., Soliven, B., and Rezania, K. (2021). Drugs that induce or cause deterioration of Myasthenia Gravis: An update. J. Clin. Med., 10.","DOI":"10.3390\/jcm10071537"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1002\/jmd2.12317","article-title":"Autoantibodies in Wilson disease: Impact on clinical course","volume":"63","author":"Eyileten","year":"2022","journal-title":"JIMD Rep."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s10545-015-9866-0","article-title":"Concomitant immune-related events in Wilson disease: Implications for monitoring chelator therapy","volume":"39","author":"Seessle","year":"2016","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/0022-510X(76)90188-X","article-title":"Immunological observations on patients with Wilson\u2019s disease","volume":"29","author":"Czlonkowska","year":"1976","journal-title":"J. Neurol. Sci."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/BF00607425","article-title":"The influence of prolonged treatment with D-penicillamine on the immune response in Wilson\u2019s disease","volume":"12","year":"1977","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1212\/01.WNL.0000137021.90567.37","article-title":"Effect of D-penicillamine on neuromuscular junction in patients with Wilson disease","volume":"63","author":"Patil","year":"2004","journal-title":"Neurology"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Antos, A., Cz\u0142onkowska, A., Bembenek, J., Skowro\u0144ska, M., Kurkowska-Jastrz\u0119bska, I., and Litwin, T. (2023). Blood based biomarkers of central nervous system involvement in Wilson\u2019s disease. Diagnostics, 13.","DOI":"10.3390\/diagnostics13091554"}],"container-title":["Life"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-1729\/13\/8\/1715\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:30:14Z","timestamp":1760128214000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-1729\/13\/8\/1715"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,10]]},"references-count":40,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2023,8]]}},"alternative-id":["life13081715"],"URL":"https:\/\/doi.org\/10.3390\/life13081715","relation":{},"ISSN":["2075-1729"],"issn-type":[{"value":"2075-1729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,10]]}}}